Sjuts Dustin S 4
4 · Revance Therapeutics, Inc. · Filed Mar 17, 2022
Insider Transaction Report
Form 4
Sjuts Dustin S
Chief Commercial Officer
Transactions
- Tax Payment
Common Stock
2022-03-15$15.79/sh−1,835$28,975→ 97,123 total
Footnotes (1)
- [F1]Represents the number of shares withheld by and surrendered to the Issuer on March 15, 2022, to satisfy tax withholding obligations that arose in connection with the vesting of Restricted Stock award (the "RSA") for 22,620 shares. The RSA vests in three equal annual installments from March 15, 2021, subject to Mr. Sjuts' Continuous Service (as defined in the Issuer's 2014 Equity Incentive Plan) on each vesting date.